The ProstaSmart device increases the effectiveness of drug therapy several times (providing an additional improvement in laboratory parameters by 42% - 72% of the initial value according to the results of clinical studies). It passed all the necessary registration studies, on the basis of which it received a registration certificate RZN 2013/82 dated April 18, 2013. In addition to the mandatory procedures, ProstaSmart underwent an in-depth clinical randomized placebo-controlled study at the Research Institute of Urology of the Russian Ministry of Health in 2014. According to the results of the study, the device is recommended for the treatment of chronic prostatitis.

The effectiveness of the ProstaSmart device is explained by two factors:

  • the beneficial effect of physiotherapeutic procedures, as well as
  • the enhanced effect of drugs (increasing their concentration and the rate of chemical reactions) in the prostate gland due to local targeted vasodilation using thermo- and infrared therapy.

ProstaSmart is a professional medical device, therefore, like any other medical device or medicine, it has its own indications and contraindications. Therefore, before the first use, a consultation with a urologist is necessary. In the absence of contraindications, ProstaSmart confirmed its safety and effectiveness in a clinical study at the Research Institute of Urology.

The main distinctive feature of ProstaSmart is the combination of physiotherapeutic effects and compact size. Thanks to technical progress, reduction in the size of electronic components and the painstaking work of our engineers, it was possible to create a lightweight and compact physiotherapeutic device in terms of impact and efficiency that is not inferior to stationary devices installed in urological offices.

Tags: ProstaSmart, FAQ